Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First Research Funded By InHealth Speaks Well For ICDs

This article was originally published in The Gray Sheet

Executive Summary

Research sponsored by the AdvaMed spin-off InHealth suggests that patients with implanted defibrillators enjoy a quality of life similar to people of the same age without ICDs

You may also be interested in...



Research In Brief

Lung tumor ablation: Radiofrequency ablation, a common treatment for small liver tumors, is also a promising treatment strategy for patients with malignant lung tumors, researchers report in The Lancet Oncology (published by Elsevier, which also publishes "The Gray Sheet") June 18. A trial of 106 lung-tumor patients unsuitable for surgery, radiation or chemotherapy led by Riccardo Lencioni, University of Pisa, found that ablation is generally safe, with no procedure-related deaths. Of the 85 patients followed at least one year, 88% showed a complete response for the targeted tumors. A randomized trial is now warranted to compare ablation to standard treatment options, such as surgery, radiation and chemotherapy, the researchers say. AngioDynamics, which makes the 1500X RF/StarBurst ablation system used in the study and is seeking a lung tumor indication for the device, funded the research

Research In Brief

Lung tumor ablation: Radiofrequency ablation, a common treatment for small liver tumors, is also a promising treatment strategy for patients with malignant lung tumors, researchers report in The Lancet Oncology (published by Elsevier, which also publishes "The Gray Sheet") June 18. A trial of 106 lung-tumor patients unsuitable for surgery, radiation or chemotherapy led by Riccardo Lencioni, University of Pisa, found that ablation is generally safe, with no procedure-related deaths. Of the 85 patients followed at least one year, 88% showed a complete response for the targeted tumors. A randomized trial is now warranted to compare ablation to standard treatment options, such as surgery, radiation and chemotherapy, the researchers say. AngioDynamics, which makes the 1500X RF/StarBurst ablation system used in the study and is seeking a lung tumor indication for the device, funded the research

Proving Value Is Eucomed’s Top Priority: An Interview With Guy Lebeau

Device makers still have a lot of work to do to convince the cost-conscious governments of Europe that their products have strong socioeconomic value, says Eucomed Chairman Guy Lebeau

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel